A diversified clinical-stage pipeline shaped by:
- Clear understanding of cancer pathways (systems biology)
- Treatments designed with pharmacological properties to match disease need
- Biomarker-driven clinical strategies with clear clinical rationale
Merrimack has a proven history of successfully discovering and developing novel therapeutics that have helped to shape new treatment strategies for patients. That includes the successful development and approval for ONIVYDE®1 (irinotecan liposome injection) to treat patients with advanced pancreatic cancer who have previously been treated with gemcitabine-based chemotherapy.
Today, that journey continues. Merrimack is developing a new generation of solutions for cancer through a focused pipeline of precise, targeted therapies. A cornerstone of our development strategy is to establish efficacy and value through clinical studies in biomarker-enriched patient populations.
1ONIVYDE® was acquired by Ipsen S.A. in April 2017.
Learn more about our ongoing studies at clinicaltrials.gov.
In addition to our existing focused clinical pipeline, we are taking a systematic approach to our preclinical development work.
These and other innovative programs utilizing our biomarker-driven approach will provide future opportunities to enter the clinic to help patients in need.
Kamoun et al., AACR, 2018.
Kamoun et al., AACR, 2017.
Raue et al., EORTC-NCI-AACR, 2018.
Alkan et al., Science Signaling, July 2018.
Alkan et al., AACR, 2018.
Discovering and developing breakthrough cancer solutions takes a collaborative effort.
Learn more about how to work with us here.